Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
- PMID: 16973389
- DOI: 10.1016/j.immuni.2006.07.013
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
Abstract
Antibodies (Abs) to RNA- and DNA-containing autoantigens are characteristic of systemic lupus erythematosus (SLE). We showed previously that Toll-like receptor (TLR) 9, recognizing DNA, is required for the spontaneous generation of DNA autoantibodies, but not for the development of lupus nephritis in susceptible mice. We report that lupus-prone mice deficient in TLR7, a receptor for ssRNA, failed to generate Abs to RNA-containing antigens (Ags) such as Smith (Sm) Ag. TLR9 and TLR7 also had dramatic effects on clinical disease in lupus-prone mice. In the absence of TLR9, autoimmune disease was exacerbated, lymphocytes and plasmacytoid DCs were more activated, and serum IgG and IFN-alpha were increased. In contrast, TLR7-deficient mice had ameliorated disease, decreased lymphocyte activation, and decreased serum IgG. These findings reveal opposing inflammatory and regulatory roles for TLR7 and TLR9, despite similar tissue expression and signaling pathways. These results have important implications for TLR-directed therapy of autoimmune disease.
Comment in
-
Tolling for autoimmunity-prime time for 7.Immunity. 2006 Sep;25(3):397-9. doi: 10.1016/j.immuni.2006.08.011. Immunity. 2006. PMID: 16979573
Similar articles
-
Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.J Autoimmun. 2010 Jun;34(4):339-48. doi: 10.1016/j.jaut.2009.11.001. Epub 2009 Nov 26. J Autoimmun. 2010. PMID: 19944565
-
Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE.Int Immunol. 2006 Aug;18(8):1211-9. doi: 10.1093/intimm/dxl067. Epub 2006 Jun 23. Int Immunol. 2006. PMID: 16798839
-
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.Eur J Immunol. 2007 Dec;37(12):3582-6. doi: 10.1002/eji.200737815. Eur J Immunol. 2007. PMID: 18034431
-
Emerging roles of TLR7 and TLR9 in murine SLE.J Autoimmun. 2009 Nov-Dec;33(3-4):231-8. doi: 10.1016/j.jaut.2009.10.001. Epub 2009 Oct 21. J Autoimmun. 2009. PMID: 19846276 Review.
-
Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus.Ann N Y Acad Sci. 2005 Dec;1062:242-51. doi: 10.1196/annals.1358.027. Ann N Y Acad Sci. 2005. PMID: 16461805 Review.
Cited by
-
Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies.Antibodies (Basel). 2024 Feb 1;13(1):10. doi: 10.3390/antib13010010. Antibodies (Basel). 2024. PMID: 38390871 Free PMC article. Review.
-
Lupus-associated innate receptors drive extrafollicular evolution of autoreactive B cells.bioRxiv [Preprint]. 2024 Jan 9:2024.01.09.574739. doi: 10.1101/2024.01.09.574739. bioRxiv. 2024. PMID: 38260501 Free PMC article. Preprint.
-
Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update.Biomedicines. 2024 Jan 9;12(1):138. doi: 10.3390/biomedicines12010138. Biomedicines. 2024. PMID: 38255243 Free PMC article.
-
Cyclical palmitoylation regulates TLR9 signalling and systemic autoimmunity in mice.Nat Commun. 2024 Jan 2;15(1):1. doi: 10.1038/s41467-023-43650-z. Nat Commun. 2024. PMID: 38169466 Free PMC article.
-
Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions.Blood Adv. 2024 Feb 13;8(3):667-680. doi: 10.1182/bloodadvances.2023010362. Blood Adv. 2024. PMID: 38113462 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
